ARAnuradha Ramamoorthy

Anuradha Ramamoorthy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anuradha Ramamoorthy has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Dosage Modifications on Efficacy: Insights from Select Tyrosine Kinase Inhibitors Approved for Treatment of Non-Small Cell Lung Cancer with EGFR Mutations

    by Santiago D. Carrasquilla, Youwei Bi, Wenjuan Gu, Amal Ayyoub, Elimika Pfuma Fletcher, Jiang Liu, Anuradha Ramamoorthy, Yuan-Li Shen, Stacy S. Shord, Issam Zineh, et al.

    Purpose: Dosage modifications, including dose interruptions and reductions, are commonly implemented to manage adverse reactions observed with oncology drugs. However, their impact on efficacy is not well understood. Here, we explored the impact of dosage modifications on progression free survival (PFS) and overall survival (OS) for four US FDA-approved tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Methods: We collected patient-level data from clinical trials supporting the original FDA approvals of afatinib, dacomitinib, mobocertinib, and osimertinib. We identified the daily dose received (DDR; a measure of the dosage received by a patient each day), dose interruptions and reductions over the treatment period. In this exploratory analysis, we used a time-dependent Cox proportional hazards model to assess the impact of DDR on PFS and landmark time-fixed Cox models at 30, 60, and 90 days from treatment initiation to assess the impact of early dose interruptions and reductions on PFS and OS.Results: While the impact of dose interruptions and reductions on the risk of death varied among the studied drugs, dose interruptions, such as interruptions for four or more consecutive days, were more often associated with a higher risk of progression or death than dose reductions. Conclusion: For the evaluated drugs as monotherapy in NSCLC with EGFR mutations, our analysis suggests that dose reductions might have a lower impact on efficacy than missing or interrupting treatment. Further studies are needed to evaluate other EGFR treatments, drug classes, and cancer types.

  • Open Access

    Human Radiolabeled Mass Balance Studies Supporting New Drugs Approved by FDA Between 2019 and 2023

    by Anuradha Ramamoorthy, Alana Chen, Edwin Chiu Yuen Chow, Daphne Guinn, Anjali Iyer, Sonia Pahwa, Yunzhao Ren, Chinmay Shukla, Suresh Doddapaneni, Zhixia Yan Danielsen

  • The Future of Clinical Translational Pharmacology

    by Matthew L. Rizk, Anuradha Ramamoorthy, Stephani L. Stancil, Abigail W. Gorman, Julie A. Johnson, John A. Wagner, Issam Zineh, Sandra A. G. Visser

    Will clinical translational pharmacology (CTP) seize the opportunity to become a leadership discipline driving the next era of patient‐centered therapeutics? This white paper, based on input and discussion from the ASCPT Summit on the Future of Clinical Translational Pharmacology, issues a bold call to action for CTP to define itself as a discipline that embraces its multidisciplinary breadth, demanding a radical shift that visibly inhabits the full scope of its multitudinous identity. We propose a five‐priority roadmap—Foundational Principles, Workforce and Leadership, Innovation and Technology, Health Equity and Global Health, and Public Visibility and Scientific Trust—to transform CTP into an engine of therapeutic advancement and optimization. The future of medicine depends on CTP's ability to lead, adapt, influence, and unify across silos, ensuring that scientific breakthroughs translate into real‐world benefit for every patient, everywhere. The next decade demands urgency, unity, and unapologetic ambition to move beyond incremental change.


  • Open Access

    Informing Dose for Pediatric Rare Diseases—A Survey of Recent Orphan Drugs Approvals

    by Elimika Pfuma Fletcher, Chloe Kim, Hannah Mei, Bilal AbuAsal, Sherbet Samuels, Rajanikanth Madabushi, Anuradha Ramamoorthy

    Collectively, pediatric rare diseases affect millions of children worldwide. Yet, treatment options are limited. Dose selection presents unique challenges in pediatric rare disease drug development. Traditional dose‐finding approaches are impractical for these populations, and conventional pediatric dosing methods like exposure matching face limitations when insufficient adult data exists. Herein, we analyzed dosing strategies and study design characteristics used for new molecular entities (NMEs) for orphan indications approved between 2013 and 2022 that included a pediatric indication at initial approval. Among 63 evaluable products included in this analysis, initial pediatric dose selection was supported by adult data in the same indication (37%), adult healthy volunteer data (33%), nonclinical data only (14%), adult data from different indications (10%), and pediatric data from different indications (5%). The use of modeling and simulation to support initial dose selection was explicitly mentioned for 21% of products. Nearly half (48%) utilized multiple data sources for dose selection. Study design characteristics included multiple dose level evaluation (49%), intra‐patient dose escalation (33%), interim pharmacokinetic evaluation (10%), pharmacokinetic/biomarker‐driven dosing (5%), and age group staggering (5%). Multiple design features were incorporated in 17% of drugs. This analysis reveals diverse approaches to pediatric dose selection in rare diseases and the use of adaptive study design elements suggests recognition of the need for flexible approaches in these challenging populations. Utility of modeling and simulation, ability to leverage all available data sources, and increased implementation of adaptive trial designs could improve dose selection and optimization in pediatric rare disease drug development.

  • Landscape of FDA‐Approved Targeted Therapies for the Treatment of Diseases with Low Frequency Molecular Subsets

    by Lois S. Akinola, Sarah Ridge, Issam Zineh, Michael A. Pacanowski, Anuradha Ramamoorthy

  • Clinical Pharmacology Guidances Advancing Drug Development and Regulatory Assessment: Role and Opportunities

    by Anuradha Ramamoorthy, Daphne Guinn, Elimika Pfuma Fletcher, Michael Pacanowski, Kellie Reynolds, James Polli, Rajanikanth Madabushi

  • Confirmatory Evidence Used in Non‐Oncologic Rare Disease New Molecular Entity Marketing Applications Approved by FDA, 2020–2023

    by Bridget M. Nugent, Anuradha Ramamoorthy, Jennifer R. Pippins, Salvatore Pepe, Mary Doi, Audrey Thomas, Brandon Bagheri, Cynthia Welsh, Rajanikanth Madabushi, Kerry Jo Lee

    Rare disease drug development is often challenging due to limited understanding of disease biology, heterogeneity, and small patient populations, among other reasons. For a new molecular entity to be approved for marketing under a new drug application or original biologics license application by the FDA's Center for Drug Evaluation and Research, the product should be shown to be both safe and effective. In some cases, one adequate and well‐controlled clinical trial and confirmatory evidence are sufficient to establish substantial evidence of effectiveness. This important topic is the focus of a September 2023 draft guidance entitled Demonstrating Substantial Evidence of Effectiveness Based on One Adequate and Well‐Controlled Clinical Investigation and Confirmatory Evidence. Most non‐oncologic rare disease marketing applications (67%) approved between 2020 and 2023 utilized a single adequate and well‐controlled trial plus confirmatory evidence to demonstrate effectiveness. Though different types of confirmatory evidence were utilized in different applications, mechanistic or pharmacodynamic evidence was used to support 77.5% of recent rare disease marketing applications that were approved based on one adequate and well‐controlled trial plus confirmatory evidence. The quantity of confirmatory evidence necessary to support effectiveness may vary across development programs. Early and frequent discussions with the Agency to align on the developmental plan will facilitate efficient drug development and regulatory assessment.


  • Therapeutic Orphan No More: Role for Clinical Pharmacology and Translational Science in Developing Therapeutics for Rare and Neglected Diseases

    by Anuradha Ramamoorthy, Islam Younis, Ya‐Feng Wen, Mai Mehanna, Kathleen M. Giacomini, Piet H. van der Graaf